In short
This article discusses a clinical trial investigating the use of Dl-Alpha Tocopherol Acetate, also known as Vitamin E, as part of the PENTO protocol for treating Medication-Related Osteonecrosis of the Jaw (MRONJ). The trial aims to assess the effectiveness of this treatment in patients who have developed jaw bone problems due to certain medications. We'll explore the trial's objectives, eligibility criteria, and potential benefits for patients suffering from this condition.
At a glance
- Trial Name
- The PENTO protocol in Medication-Related Osteonecrosis of the Jaw (MRONJ)
- Primary Objective
- Assess healing (bone exposure area < 5 mm) in patients receiving PENTO for osteochimionecrosis at 12 months
- Key Inclusion Criteria
- Age ≥ 18, current/past treatment with bisphosphonates or targeted therapies, AAOMS Stage 2 MRONJ
- Key Exclusion Criteria
- History of head/neck radiotherapy, recent MRONJ surgery, pregnancy, severe medical conditions
- Primary Endpoint
- Percentage of patients with bone exposure area < 5 mm at 12 months
- Secondary Endpoints
- Changes in SOMA score, nutritional parameters, bone exposure area, and treatment tolerance
- Drug Information
- Dl-Alpha Tocopherol Acetate (Vitamin E), part of PENTO protocol, maximum daily dose 1000 mg
- Treatment Duration
- 12 months
What is DL-ALPHA TOCOPHEROL ACETATE?
DL-ALPHA TOCOPHEROL ACETATE is a form of vitamin E that is being studied as part of a treatment protocol for a specific medical condition. It is also known by several other names, including:
- all-rac-alfa-Tocopheryl acetate
- DL-ALPHA-TOCOPHERYL ACETATE
- DL-ALPHA-TOCOFERIL ACETATE
- DL-ALPHA-TOCOPHEROL ACETATE
- ALL-RAC-ALPHA-TOCOPHERYL ACETATE
- ALL-RAC-ALPHA-TOCOPHEROL ACETATE
This substance is classified as a chemical and is typically administered orally. It belongs to a group of medications known as tocopherols, which are forms of vitamin E.
Medical Condition: Medication-Related Osteonecrosis of the Jaw (MRONJ)
DL-ALPHA TOCOPHEROL ACETATE is being studied as part of a treatment for a condition called Medication-Related Osteonecrosis of the Jaw (MRONJ). This is a serious side effect that can occur in some patients who have taken certain medications, particularly those used to treat bone disorders or cancer.
MRONJ is characterized by exposed bone in the jaw that doesn't heal properly. It can cause pain, difficulty eating, and other oral health problems. The condition is often associated with medications such as bisphosphonates (used to treat osteoporosis) or certain targeted cancer therapies.
The PENTO Protocol: A Potential Treatment for MRONJ
Researchers are investigating a treatment approach called the PENTO protocol for patients with MRONJ. This protocol includes DL-ALPHA TOCOPHEROL ACETATE (vitamin E) along with other medications. The full name of the protocol is "pentoxifylline, retinol acetate, and DL-alpha tocopherol acetate."
The study aims to see if this combination of medications can help heal the exposed bone areas in patients with MRONJ. The treatment is given over a 12-month period, and researchers will measure how well it works by looking at the size of the exposed bone area and other factors.
Eligibility Criteria for the PENTO Protocol Study
To participate in this study, patients must meet certain criteria. Some key points include:
- Being 18 years or older
- Having a current or past treatment with certain bone medications or cancer therapies
- Having signs and symptoms of MRONJ for more than 8 weeks
- Being diagnosed with Stage 2 MRONJ according to specific medical criteria
There are also several conditions that would prevent a person from participating in the study, such as a history of head or neck radiation therapy, recent surgery for MRONJ, pregnancy, or certain medical conditions.
Study Objectives and Endpoints
The main goal of this study is to see how many patients experience healing of their MRONJ after 12 months of treatment with the PENTO protocol. Healing is defined as having an exposed bone area smaller than 5 mm.
Researchers will also look at other factors, including:
- Changes in pain levels and ability to chew
- Improvements in nutrition (measured by weight, body mass index, and certain blood tests)
- How quickly the exposed bone area gets smaller
- Any side effects of the treatment
Potential Benefits and Risks
While the PENTO protocol, including DL-ALPHA TOCOPHEROL ACETATE, shows promise for treating MRONJ, it's important to note that this is still an experimental treatment. The study aims to determine how effective and safe it is.
Potential benefits could include healing of the exposed bone, reduced pain, and improved quality of life. However, as with any medical treatment, there may be risks or side effects. The study will carefully monitor patients for any adverse events throughout the 12-month treatment period.
It's crucial for patients to discuss the potential benefits and risks with their healthcare provider before considering participation in this or any clinical trial.